论文部分内容阅读
目的:观察心可舒对冠状动脉慢血流(CSF)患者血清炎性因子的影响及临床疗效。方法:选择2010-2014年因胸痛行冠状动脉造影(CAG)被诊断为CSF的患者110例,随机分为观察组和对照组各55例。对照组给予常规抗心绞痛药物治疗(扩冠、调脂、抗血小板等),观察组在对照组治疗的基础上加用心可舒治疗。治疗前、治疗后6个月,测定两组患者血清超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、脂联素水平的变化,同时采用门控心肌灌注断层显像(G-MPI)检查评估受损心肌改善情况。结果:治疗前两组血清hs-CRP、Hcy及脂联素水平均差异不显著(P>0.05);治疗后观察组脂联素水平显著高于对照组(P<0.05),hs-CRP和Hcy水平显著低于对照组(P<0.05)。观察组受损心肌改善率为79.5%,显著高于对照组的53.4%(P<0.05)。结论:心可舒能够显著降低CSF患者血清炎性因子水平,对CSF有较好的临床效果。
Objective: To observe the effect of Xinkuxu on serum inflammatory factors in patients with chronic coronary artery disease (CSF) and its clinical efficacy. Methods: A total of 110 patients with CSF diagnosed by coronary angiography (CAG) during 2010-2014 were randomly divided into observation group (55 cases) and control group (55 cases). Control group was given conventional anti-anginal drug therapy (crown expansion, lipid-lowering, anti-platelet, etc.). The observation group was treated with XK on the basis of the control group. The levels of hs-CRP, Hcy and adiponectin in the two groups were measured before treatment and 6 months after the treatment. The changes of the levels of serum hs-CRP, (G-MPI) examination to assess the improvement of impaired myocardium. Results: The levels of serum hs-CRP, Hcy and adiponectin in the two groups before treatment were not significantly different (P> 0.05). After treatment, the levels of adiponectin in the observation group were significantly higher than those in the control group (P <0.05) Hcy levels were significantly lower than the control group (P <0.05). The improvement rate of myocardial damage in observation group was 79.5%, which was significantly higher than that in control group (53.4%, P <0.05). Conclusion: XK can significantly reduce the level of serum inflammatory cytokines in patients with CSF, have a better clinical effect of CSF.